Alagille Syndrome Treatments

Find Alagille Syndrome Treatments

Brand Name

Livmarli

Generic Name
Maralixibat
View Brand Information
FDA approval date: September 29, 2021
Classification: Ileal Bile Acid Transporter Inhibitor
Form: Tablet, Solution

What is Livmarli (Maralixibat)?

LIVMARLI is an ileal bile acid transporter inhibitor indicated for: the treatment of cholestatic pruritus in patients 3 months of age and older with Alagille syndrome .
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

A Cohort Study to Investigate the Risk of Liver Disorder of Livmarli Oral Solution in Patients With Japan Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) Registered in the Comprehensive and Informative Registry System for Childhood Liver Disease (CIRCLe)

Summary: This study is a database study in Japan for maralixibat (TAK-625) used to treat participants with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC). The main aim of the study is to evaluate the risk of liver disorder during the use of maralixibat in Japanese patients with ALGS or PFIC. This database study will conduct in use of medical database called Comprehensive ...

Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)

Summary: The key objectives of this low-intervention clinical study are to evaluate tolerability, long-term safety and long-term efficacy for patients with Alagille syndrome (ALGS) who are prescribed Livmarli.

Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

Summary: The objective of this 5-year, prospective, observational cohort study is to evaluate the long-term safety and clinical outcomes of patients with Alagille syndrome (ALGS) or Progressive familial intrahepatic cholestasis (PFIC) treated with Livmarli.